Vericel Corporation (NASDAQ: VCEL) is a Healthcare company (Biotechnology) with a market capitalization of $3.0B. The Maz Rating grades it against the other companies in its sector.
Vericel Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $57.88, Vericel Corporation trades at 87.9x trailing earnings, 9.1x sales and 7.7x book value, with an EV/EBITDA of 59.9. Over the last twelve months it generated about $323M of revenue and $34M of net income. It runs a gross margin of 74.5%, an operating margin of 8.3% and a net margin of 10.3%. It shows return on equity of 9.1%, return on invested capital of 5.5% and a free cash flow yield of 1.6%. On the balance sheet: a debt-to-equity ratio of 0.24 and a current ratio of 5.13. Over the past 52 weeks the share price ranged from $28.95 to $59.75, with a beta of 1.06.
Vericel Corporation does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 9 Buy and 5 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.